# Dupilumab for Eosinophilic Esophagitis With Severe Strictures

> **NCT06352073** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 23 (actual)

## Conditions studied

- Eosinophilic Esophagitis
- EoE

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT06352073
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-16
- **Primary completion:** 2026-04-16
- **Final completion:** 2026-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06352073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06352073, "Dupilumab for Eosinophilic Esophagitis With Severe Strictures". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06352073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*